Vyne Therapeutics Inc (VYNE) - Total Assets
Based on the latest financial reports, Vyne Therapeutics Inc (VYNE) holds total assets worth $30.16 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vyne Therapeutics Inc - Total Assets Trend (2015–2025)
This chart illustrates how Vyne Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see market value of Vyne Therapeutics Inc for the company's overall valuation and market capitalisation.
Vyne Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Vyne Therapeutics Inc's total assets of $30.16 Million consist of 99.5% current assets and 0.5% non-current assets. Review VYNE total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Vyne Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Vyne Therapeutics Inc (VYNE) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vyne Therapeutics Inc's current assets represent 99.5% of total assets in 2025, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 79.7% of total assets in 2025, down from 99.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Vyne Therapeutics Inc Competitors by Total Assets
Key competitors of Vyne Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Vyne Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.53 | 4.35 | 6.64 |
| Quick Ratio | 12.53 | 4.35 | 6.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $27.61 Million | $49.62 Million | $121.57 Million |
Vyne Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Vyne Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.79 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | -54.9% |
| Total Assets | $30.16 Million |
| Market Capitalization | $22.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vyne Therapeutics Inc's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vyne Therapeutics Inc's assets decreased by 54.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vyne Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Vyne Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $30.16 Million | -54.92% |
| 2024-12-31 | $66.91 Million | -31.51% |
| 2023-12-31 | $97.69 Million | +139.67% |
| 2022-12-31 | $40.76 Million | -39.21% |
| 2021-12-31 | $67.05 Million | -28.48% |
| 2020-12-31 | $93.74 Million | +18.41% |
| 2019-12-31 | $79.17 Million | -43.42% |
| 2018-12-31 | $139.93 Million | +109.26% |
| 2017-12-31 | $66.87 Million | +59.01% |
| 2016-12-31 | $42.05 Million | -4.17% |
| 2015-12-31 | $43.88 Million | -- |
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more